The capacity of the gp41-directed agents to block infection post CD4 recruitment, is in line with previous reports observing MPER mAbs and HR1 and HR2 targeting inhibitors which act at a prefusion stage [57], [58], [62], [63], [64], [65], [66]. The gene discussed is CD4; the disease is infection.